Lung Cancer Data and Biotech Shifts
Kilder
- STAT: STAT+: GSK touts lung cancer data from two drugs
- BioPharma Dive: Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
- Finance: Cellectis Announces In Vivo Gene Editing Transformation, Exits Lasme-cel and Eti-cel Development - Yahoo Finance
- Endpoints: Electra aims for nearly $300M IPO; Enhertu’s Phase 3 lung cancer success - Endpoints News
- Endpoints: Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.